NEWS & EVENTS

Press Releases

  Sign up for email alerts:      


30.12.11 Total Voting Rights
20.12.11 Additional Listing
12.12.11 Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
07.12.11 Silence Therapeutics announces positive outcome from oral hearing at the European Patent Office
08.11.11 Silence Therapeutics provides corporate and development update
24.10.11 Silence Therapeutics signs collaboration with Mirna Therapeutics to evaluate delivery of novel microRNA therapeutics
14.10.11 Grant of Options
03.10.11 Directors' share purchases
27.09.11 Silence Therapeutics signs siRNA delivery collaboration with top 10 pharma company
21.09.11 Interim Results for the Six Months Ended 30 June 2011
21.09.11 Appointment of Chief Business Officer
20.09.11 Appointment of Chief Executive Officer
16.09.11 Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
14.09.11 Notice of Results
12.09.11 Silence Therapeutics and InteRNA Technologies sign collaboration to develop novel microRNA therapeutics
08.09.11 Silence Therapeutics to Present at Upcoming Investor Conferences
03.08.11 Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
01.08.11 Group Reorganisation and Board Changes
21.06.11 Holding in Company
13.06.11 Results of Annual General Meeting
06.06.11 Silence Therapeutics' Atu027 Demonstrates Promising Antitumor Activity in Phase I Study Presented at ASCO
01.06.11 Silence Therapeutics Post-Fundraising Update
25.05.11 Holding in Company
19.05.11 Holding in Company
18.05.11 Silence Therapeutics to Present New Data from Phase I Study with Atu027 at 2011 ASCO Annual Meeting
18.05.11 Publication of 2010 Annual Report and Notice of AGM
18.05.11 Holding in Company
17.05.11 Holding in Company
17.05.11 Holding in Company
17.05.11 Holding in Company
16.05.11 Grant of options and warrants
16.05.11 Silence Therapeutics Result of Placing and Open Offer
16.05.11 Silence Therapeutics Result of General Meeting
12.05.11 Holding in Company
03.05.11 Silence Therapeutics Issued Japanese Patent Covering Its Core RNA Interference (RNAi) Technology
27.04.11 Silence 2010 Full Year Results
27.04.11 Silence Announces Financing
07.04.11 Holding in Company
30.03.11 Silence Therapeutics’ Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
21.03.11 Silence Therapeutics’ Partner Quark Pharmaceuticals Announces Results from Phase 2 PF-04523655 Study in Diabetic Macular Edema
23.02.11 Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
14.02.11 Silence Therapeutics to Present at 13th Annual BIO CEO & Investor Conference
07.02.11 Termination of Offer Period

 

21.12.10 Silence Therapeutics Provides Year-end Update
11.11.10 Holding in Company
10.11.10 Silence Therapeutics’ Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
20.10.10 Silence Therapeutics Receives Comprehensive Protection for RNAI Structural Modification Technology in Single European Patent
20.09.10 Interim Results for the Six Months Ended 30 June 2010
14.09.10 Change of Nomad
08.09.10 Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
06.09.10 Potential Offer
19.08.10 Silence Therapeutics’ Partner Quark Signs Exclusive Option Agreement with Novartis for Development and Commercialisation of QPI-1002
18.08.10 Change of Auditor and Notice of Interim Results
11.08.10 Silence Therapeutics Adds New Patent to Industry Leading Structural Modification Intellectual Property Portfolio
14.07.10 Holding in Company
14.07.10 Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
07.07.10 Silence Therapeutics Expands RNAi Structural Modification IP Portfolio with Issuance of New U.S. Patent
18.06.10 All resolutions passed at Annual General Meeting
09.06.10 Silence Therapeutics Announces Issuance of New U.S. Patent Broadly Covering Methods for Enhancing Silencing Activity of RNAi Therapeutics
26.05.10 Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
11.05.10 Silence Therapeutics to Present at Upcoming Investor Conferences
05.05.10 Silence Therapeutics Appoints New Vice President of Research
29.04.10 Silence Therapeutics Plc Unaudited Preliminary Results for the Year Ended 31 December 2009
28.04.10 Notification of Results
21.04.10 Silence Therapeutics and AstraZeneca Extend siRNA Delivery Collaboration
15.04.10 Silence Therapeutics Appoints Max Herrmann as Chief Financial Officer
13.04.10 Silence Therapeutics Executes Strategic Plan to Optimize and Integrate Technologies and Assets from Intradigm Merger
30.03.10 Silence Therapeutics and Dainippon Sumitomo Expand siRNA Delivery Collaboration
19.03.10 Holding in Company
01.03.10 Silence Therapeutics plc Announces Changes to Management and the Board of Directors
15.02.10 Director’s Dealings
12.02.10 Notification of Results
12.02.10 Jerry Randall has been appointed Senior Independent Director
08.02.10 Silence Therapeutics Receives Notice of Allowance for RNA Interference (RNAi) Patent Covering Novel Cancer Target
05.02.10 Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
28.01.10 Issued share capital - total voting rights
08.01.10 Holding in Company
05.01.10 Silence Therapeutics announces completion of merger with Intradigm Corporation and issue of new shares
04.01.10 All resolutions passed at Extraordinary General Meeting
17.12.09 Posting of the Admission Document to Shareholders
16.12.09 Silence Therapeutics to merge with Intradigm Corp to create leading RNAi therapeutics company
16.12.09 Admission Document
14.12.09 AGM announcement
15.10.09 Silence Therapeutics’ core patent upheld by the European Patent Office
20.11.09 Notice of AGM
20.11.09 Full Notice of AGM and Proxy Form 
30.09.09 Interim Results for the Six Months Ended 30 June 2009
29.09.09 Merger discussions
17.09.09 Notification of Results
28.08.09 Holding in Company
27.08.09 Silence Therapeutics signs siRNA delivery collaboration with Dainippon Sumitomo Pharma
26.08.09 Holding in Company
14.07.09 Issue of shares pursuant to exercise of options
24.06.09 Silence Therapeutics publishes 2008 Annual report and Accounts
23.06.09 Silence announces dosing of first patient in Atu027 cancer trial
03.06.09 Silence receives approval to commence Phase I clinical trial with Atu027
01.04.09 Silence issues Unaudited Preliminary Results for the year ended 31 December 2008
30.03.09 Notification of Results
19.03.09 Holding in Company
16.02.09 Holding in Company
21.01.09 Silence Therapeutics announces its successful opposition to second European Patent in Kreutzer-Limmer patent family
19.01.09 Holding in Company
15.01.09 Total Voting Rights
15.01.09 Holding in Company
12.01.09 Change of address
09.01.09 European Patent Office grants Silence Therapeutics’ Patent on Target for Lead Compound Atu027
08.01.09 Silence Therapeutics’ partner Quark initiates next stage of clinical trials on DGF
08.01.09 Gartmore takes significant stake in Silence Therapeutics plc
31.12.08 Total Voting Rights
11.12.08 Holding in Company
10.12.08 Silence Therapeutics’ position is strengthened after European Patent Office revokes competitor RNA interference patent in its entirety
05.12.08 Grant of Options
05.12.08 Exercise of options by staff
04.12.08 Silence Therapeutics to make regulatory filing to take lead cancer therapy Atu027 into the clinic
01.12.08 Silence Therapeutics publishes comprehensive research showing that its lead candidate Atu027 inhibits cancer progression
18.11.08 United States Patent and Trademark Office grants Silence Therapeutics Core RNAi Patent
13.11.08 Holding in Company
29.10.08 Holding in Company
27.10.08 Silence Therapeutics announces Directors share purchases
22.10.08 Silence Therapeutics announces Directors share purchases
22.10.08 Silence Therapeutics announces Directors share purchases
17.10.08 AGM Statement 2008
08.10.08 Holding in Company
26.09.08 Grant of Options
26.09.08 European Patent Office raises serious concerns about legal validity of fundamental RNA interference patent
25.09.08 Interim Results for the Six Months Ended 30 June 2008
25.09.08 Notice of AGM to be held on October 17 2008
24.09.08 Holding in Company
29.08.08 Holding in Company
26.08.08 Holding in Company
07.08.08 Holding in Company
05.08.08 Holding in Company
31.07.08 Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
30.07.08 Silence Therapeutics Patent Update
30.07.08 Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial
25.07.08 Holding in Company
24.07.08 Timing of Annual General Meeting and of Interim Results Announcement
24.07.08 Holding in Company
23.07.08 European Patent Office issues notice of intent to grant patent for lead product
18.07.08 Holding in Company
17.07.08 Organisational Changes
11.07.08 Silence Therapeutics Announces Successful Opposition of Glover Patent
01.07.08 Silence Therapeutics Announces Board Changes
25.06.08 Silence announces FDA grants IND to Quark for AtuRNAi based siRNA product
24.06.08 Holding in Company
18.06.08 Holding in Company
09.06.08 Silence Therapeutics to Present at Upcoming Biotechnology Industry Conferences
05.06.08 Holding in Company
27.05.08 Holding in Company
16.05.08 Holding in Company
06.05.08 Jeff Vick, CEO of Silence Therapeutics to Present at Rodman and Renshaw's 5th Annual Global Healthcare Conference
07.04.08 Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
01.04.08 Silence Therapeutics announces Directors share purchases
31.03.08 Silence Therapeutics announces Directors share purchases
27.03.08 Silence Therapeutics plc announces its Preliminary Unaudited Results for the year ended 31 December 2007
20.03.08 Holding in Company
19.03.08 The Preliminary Unaudited Results for the year ended 31 December 2007 will be announced on 27 March 2008
19.03.08 Holding in Company
13.03.08 Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
05.02.08 Holding in Company
30.01.08 Holding in Company
23.01.08 Holding in Company
21.01.08 Holding in Company
17.01.08 Holding(s) in Company
02.01.08 Holding in Company
02.01.08 Holding in Company
24.12.07 Share issue
17.12.07 Share price movement
12.12.07 Holding in Company
04.12.07 Holding in Company
26.11.07 Holding in Company
23.11.07 Holding in Company
20.11.07 Silence Therapeutics Appoints Financial Adviser and Broker and Nominated Adviser
19.11.07 Silence Therapeutics plc announces that a 2nd siRNA therapeutic based upon its unique proprietary chemistry has moved into clinical development
19.11.07 Silence Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
05.11.07 Holding in Company
02.11.07 Silence Therapeutics to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
29.10.07 Holding in Company
29.10.07 Total Voting Rights~
25.10.07 Holding in Company
22.10.07 Holding in Company
09.10.07 Exercise of options
02.10.07 Directors dealings
28.09.07 Interim Results for the Six Months Ended 30 June 2007 ([click to download Interim Report])
10.09.07 Silence Therapeutics RNAi Lead Compound Atu027 Successfully Completes 28-Day Toxicology Studies
06.09.07 Notice of Interim Results
04.09.07 Holding in Company
24.08.07 Holding in Company
23.08.07 Holding in Company
20.08.07 Holding in Company
16.08.07 Holding in Company
16.08.07 Holding in Company
16.08.07 Compliance with AIM Rule 26
09.08.07 9 August 2007 (pm) Holding in Company
09.08.07 9 August 2007 (am) Holding in Company
02.08.07 Holding in Company
02.08.07 Result of AGM
31.07.07 Silence Therapeutics And Quark Pharmaceuticals Expand Strategic Licensing Agreement
31.07.07 Total Voting Rights
30.07.07 Holding in Company
27.07.07 Silence Therapeutics strengthens Management Team with the appointment of CEO
20.07.07 Holding in Company
13.07.07 Holding in Company
11.07.07 Holding in Company
10.07.07 Holding in Company
08.07.07 Notice of Annual General Meeting
06.07.07 Exercise of options by staff
06.07.07 Silence Therapeutics signs siRNA collaboration with AstraZeneca to develop Novel Respiratory Therapeutics
02.07.07 Exercise of options by staff
28.06.07 Annual Report and Accounts 2006 and Annual General Meeting
26.06.07 Total voting rights
21.06.07 Holding in Company
20.06.07 Holding in shares
15.06.07 Silence Therapeutics to Present at Piper Jaffray 2nd Annual Healthcare Conference
14.06.07 Exercise of options by staff
13.06.07 Holdings in shares
06.06.07 Holdings in shares
04.06.07 Holdings in shares
30.05.07 Holdings in shares
29.05.07 Holdings in shares
29.05.07 Holdings in shares
21.05.07 Exercise of options by staff
11.05.07 Major Shareholder (pdf)
09.05.07 Exercise of options by staff (pdf)
30.04.07 Total Voting Rights (pdf)
26.04.07 EGM Statement (pdf)
23.04.07 Share issue – staff options (pdf).
04.04.07 Grant of Options (pdf).
04.04.07 Notification of share purchase by SR Pharma Chairman (pdf).
30.03.07 Extraordinary General Meeting (pdf).
30.03.07 SR Pharma announces Preliminary Unaudited 2006 Results (pdf).
30.03.07 Notice of Extraordinary General Meeting (pdf).
16.03.07 SR Pharma plc announces IND for a 2nd siRNA therapeutic based on its unique proprietary chemistry (pdf).
28.02.07 Holding in Company – Cantor Fitzgerald (pdf).
22.02.07 Holding in company - Man Financial Ltd (pdf).
21.02.07 SR Pharma - RNAi Technology Briefing (pdf).
21.02.07 Holding in Company (pdf).
09.02.07 Holding in company - Man Financial Ltd (pdf).
05.02.07 Commencement of clinical trials by licence partner (pdf).
30.01.07 SR Pharma plc Announces the Successful Completion of Additional Toxicology Studies for its Systemically Delivered RNAi Compound (pdf).
19.01.07 Holding in company - Fidelity (pdf).
03.01.07 SR Pharma granted Core RNAi patent by the European Patent Office (pdf).
29.11.06 SR Pharma plc Announces Superior Theraupeutic Efficcacy of Atu027 RNAi in Pre-Clinical Models of Pancreatic Cancer Compared to Gemcitabine® (pdf).
27.11.06 Grant of Options (pdf).
23.11.06 Share Issue – Staff Options (pdf).
20.11.06 Placing of Shares – AIM Fund non notifiable (pdf).
16.11.06 Holdings in Company (pdf).
13.11.06 SR Pharma plc Announces the Successful Completion of Toxicology Studies for it’s Systematically Delivered RNAi Product Candidate Atu027 (pdf).
06.11.06 Placing of Shares (pdf).
04.10.06 Holding in company - Fidelity (pdf).
29.09.06 Holding in company - Fidelity (pdf).
28.09.06 Holding in company - Man Financial Ltd (pdf).
28.09.06 SR Pharma plc Unaudited interim results for the six months ended 30 June 2006 (pdf).
27.09.06 Holding in company - Man Financial Ltd (pdf).
26.09.06 SR Pharma plc to Receive Milestone Payments of up to US$95 Million (~£50 Million) from Pfizer as a Result of a Sublicensing Deal (pdf).
13.09.06 SR Pharma plc Announces Encouraging Results for Atu027 RNAi Showing Therapeutic Efficacy in Mouse Models of Pancreatic Cancer (pdf).
1.09.06 Holding in Company AIM Real fund holding (pdf).
24.08.06 Holding in Company Artemis shares (pdf).
29.06.06 SR Pharma plc Annual Report for the year ended 2005 (pdf).
23.06.06 SR Pharma plc welcomes the European Patent Office decision to limit the scope of Kreutzer-Limmer RNAi Patent claim (pdf).
15.06.06 SR Pharma plc establishes GMP production with partners for its lead RNAi therapeutic product, Atu027 (pdf).
06.06.06 SR Pharma plc announces a key technical breakthrough with its lyophilized (dry powder) liposomal-based siRNA formulation (pdf).
03.05.06 Conversion of Warrants (pdf).
24.04.06 SR Pharma plc announces two key scientific publications on therapeutic RNAi in Gene Therapy (pdf).
28.03.06 SR Pharma plc announces Licence with Merck & Co (pdf).